Trials / Withdrawn
WithdrawnNCT02597465
A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 in Subjects With Cancer
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sun Pharma Advanced Research Company Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open label study to determine the efficacy and safety of SPARC1507
Detailed description
Subjects with advanced Biliary tract carcinoma meeting the eligibility criteria will be randomized in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPARC1507 | The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle |
| DRUG | Reference1507 | Investigators choice including chemotherapy or supportive therapy |
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2019-03-01
- Completion
- 2019-12-01
- First posted
- 2015-11-05
- Last updated
- 2020-12-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02597465. Inclusion in this directory is not an endorsement.